Posted: 6 August 2025
BioNTech has officially launched a new Clinical Trial Oncology Platform in partnership with the Peter MacCallum Cancer Centre, aimed at expanding access to investigational cancer treatments across Victoria. The initiative, backed by the Allan Labor Government, marked a major milestone in the state’s ambition to remain at the forefront of global medical research and mRNA innovation.
During a visit to the centre, Minister for Economic Growth and Jobs Danny Pearson highlighted the platform’s potential to deliver breakthrough treatments: “Victoria has some of the best cancer survival outcomes globally, but there’s more to do – this new Clinical Trial Oncology Platform has the potential to deliver the next big breakthrough in cancer treatment.”
The platform was developed through a formal agreement between BioNTech and Peter Mac, creating a collaborative network that includes Austin Health, Alfred Health, and Monash Health. Its design aims to simplify and accelerate clinical trials through better planning, data collection, and streamlined patient access.
The first clinical trial, launched at Peter Mac, is evaluating an investigational immunotherapy combined with chemotherapy for people with triple-negative breast cancer. Future trials will target other common and hard-to-treat cancers such as lung, melanoma, and head and neck cancers.
As part of a broader strategic partnership with mRNA Victoria, BioNTech is also constructing a cutting-edge mRNA manufacturing facility at La Trobe University’s Bundoora campus to support clinical-stage production of mRNA-based medicines.
BioNTech’s Site Head Australia, David Sparling, emphasised: “By harnessing the strength of Victoria’s life sciences sector, we aim to streamline clinical trials and expedite the development of innovative investigational treatments for people with cancer.”
The Victorian Government has committed $5 million to grow clinical trial capacity and invested over $1 billion in health and medical research over the past decade.
For more information click here.
